Cargando…

Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting

Although it has been shown in murine models that chemoradiotherapy may induce immunogenic tumor cell death, which could trigger T-cell immunity upon the released of high-mobility group box 1 protein (HMGB1), whether this also occurs in clinical settings remains unclear. Here, we discuss tumor-antige...

Descripción completa

Detalles Bibliográficos
Autores principales: Kono, Koji, Mimura, Kousaku
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583908/
https://www.ncbi.nlm.nih.gov/pubmed/23482346
http://dx.doi.org/10.4161/onci.22197
_version_ 1782475503963209728
author Kono, Koji
Mimura, Kousaku
author_facet Kono, Koji
Mimura, Kousaku
author_sort Kono, Koji
collection PubMed
description Although it has been shown in murine models that chemoradiotherapy may induce immunogenic tumor cell death, which could trigger T-cell immunity upon the released of high-mobility group box 1 protein (HMGB1), whether this also occurs in clinical settings remains unclear. Here, we discuss tumor-antigen specific T-cell responses in esophageal cancer patients receiving chemoradiotherapy. Our findings indicate that chemoradiation induces tumor antigen-specific T-cell responses and that the release of HMGB1 is related to clinical outcome.
format Online
Article
Text
id pubmed-3583908
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35839082013-03-11 Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting Kono, Koji Mimura, Kousaku Oncoimmunology Author's View Although it has been shown in murine models that chemoradiotherapy may induce immunogenic tumor cell death, which could trigger T-cell immunity upon the released of high-mobility group box 1 protein (HMGB1), whether this also occurs in clinical settings remains unclear. Here, we discuss tumor-antigen specific T-cell responses in esophageal cancer patients receiving chemoradiotherapy. Our findings indicate that chemoradiation induces tumor antigen-specific T-cell responses and that the release of HMGB1 is related to clinical outcome. Landes Bioscience 2013-01-01 /pmc/articles/PMC3583908/ /pubmed/23482346 http://dx.doi.org/10.4161/onci.22197 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Kono, Koji
Mimura, Kousaku
Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting
title Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting
title_full Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting
title_fullStr Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting
title_full_unstemmed Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting
title_short Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting
title_sort immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583908/
https://www.ncbi.nlm.nih.gov/pubmed/23482346
http://dx.doi.org/10.4161/onci.22197
work_keys_str_mv AT konokoji immunogenictumorcelldeathinducedbychemoradiotherapyinaclinicalsetting
AT mimurakousaku immunogenictumorcelldeathinducedbychemoradiotherapyinaclinicalsetting